SPL Medical announces the first time mentioning of its novel contrast agent Ferrotran® (Ferumoxtran) in the German S3-guidelines for Prostate Cancer

SPL Medical announces the first time mentioning of its novel contrast agent Ferrotran® (Ferumoxtran) in the German S3-guidelines for Prostate Cancer

Novel imaging agent mentioned in German S3-Guidelines Prostate Cancer

Nijmegen, Netherlands, 27.05.2021 – SPL Medical announced today that the new issue of the German S3-guidelines for prostate cancer, released this month by the Guideline Program Oncology of the German Cancer Society, Deutsche Krebshilfe and AWMF, for the first time is mentioning Ferrotran® (Ferumoxtran) on page 25 of the Guideline Report document.

No Comments

Sorry, the comment form is closed at this time.